Spojené štáty - angličtina - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets usp are indicated for the treatment of hypertension. enalapril maleate tablets usp are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of enalapril maleate tablets usp and thiazides are approximately additive. heart failure enalapril maleate tablets usp are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets usp improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets usp decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in using enalapril maleate tablets usp consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets usp does not have a similar risk (see warnings, neutropenia/agranulocytosis). in considering use of enalapril maleate tablets usp, it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. do not coadminister aliskiren with enalapril maleate in patients with diabetes (see precautions, drug interactions ). enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings, head and neck angioedema ).

Spojené štáty - angličtina - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets usp are indicated for the treatment of hypertension. enalapril maleate tablets usp are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of enalapril maleate tablets usp and thiazides are approximately additive. heart failure enalapril maleate tablets usp are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets usp improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets usp decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in using enalapril maleate tablets usp consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets usp does not have a similar risk (see warnings, neutropenia/agranulocytosis). in considering use of enalapril maleate tablets usp, it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. do not coadminister aliskiren with enalapril maleate in patients with diabetes (see precautions, drug interactions ). enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings, head and neck angioedema ).

Spojené štáty - angličtina - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets usp are indicated for the treatment of hypertension. enalapril maleate tablets usp are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of enalapril maleate tablets usp and thiazides are approximately additive. heart failure enalapril maleate tablets usp are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets usp improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets usp decreases the rate of development of overt heart failure and decreases

Spojené štáty - angličtina - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets usp are indicated for the treatment of hypertension. enalapril maleate tablets usp are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of enalapril maleate tablets usp and thiazides are approximately additive. heart failure enalapril maleate tablets usp are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets usp improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets usp decreases the rate of development of overt heart failure and decreases

Spojené štáty - angličtina - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension enalapril maleate tablets usp are indicated for the treatment of hypertension. enalapril maleate tablets usp are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of enalapril maleate tablets usp and thiazides are approximately additive. heart failure enalapril maleate tablets usp are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets usp improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets usp decreases the rate of development of overt heart failure and decreases

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

multichem nz limited - enalapril maleate 10mg;   - tablet - 10 mg - active: enalapril maleate 10mg   excipient: hypromellose iron oxide red lactose maize starch purified talc stearic acid - all grades of essential hypertension.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

multichem nz limited - enalapril maleate 20mg;   - tablet - 20 mg - active: enalapril maleate 20mg   excipient: ferrous oxide hypromellose lactose maize starch purified talc stearic acid - all grades of essential hypertension.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 4 mg - capsule - excipient ingredients: croscarmellose sodium; sodium stearylfumarate; titanium dioxide; gelatin; maize starch; povidone; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 2 mg - capsule - excipient ingredients: brilliant blue fcf; maize starch; sodium stearylfumarate; erythrosine; lactose monohydrate; allura red ac; titanium dioxide; povidone; gelatin; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 1 mg - capsule - excipient ingredients: titanium dioxide; croscarmellose sodium; gelatin; erythrosine; povidone; sunset yellow fcf; lactose monohydrate; sodium stearylfumarate; maize starch; brilliant blue fcf; allura red ac; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).